Immunotherapy Reduces Plaque in Mouse Arteries, Suggesting Coronary Disease Intervention

Why It Matters

The therapy tackles residual plaque that statins cannot remove, offering a potential means to prevent heart attacks in high‑risk patients. It also brings immunotherapy, previously confined to oncology, into cardiovascular disease treatment.

Key Takeaways

• BiTE therapy targets FAP+ smooth muscle cells, reducing plaque.
• Mouse models showed decreased inflammation and improved plaque stability.
• Potential complement to statins for patients with residual plaque.
• FAP imaging tracer may identify high‑risk coronary lesions.

Pulse Analysis

Coronary artery disease remains the leading cause of mortality worldwide, and despite widespread use of statins and lifestyle interventions, many patients retain significant atherosclerotic plaque that continues to drive events. Traditional lipid‑lowering drugs primarily prevent new plaque formation but do little to remodel existing lesions, leaving a therapeutic gap for those with advanced disease. The emergence of precision immunotherapies promises to fill this void by directly targeting cellular drivers of plaque growth and instability.

The bispecific T‑cell engager (BiTE) platform, long employed in oncology to redirect T cells against tumor antigens, has been repurposed to recognize fibroblast activation protein (FAP) on modulated vascular smooth‑muscle cells. In pre‑clinical mouse models, a half‑life‑extended anti‑FAP BiTE efficiently depleted these pathogenic cells, resulting in markedly lower plaque burden, reduced inflammatory infiltrates, and more stable fibrous caps. By eliminating the cellular source of pro‑inflammatory signals, the approach addresses both plaque size and vulnerability, offering a dual benefit that statins alone cannot achieve.

Looking ahead, the research team plans to file an IND within three years while refining the BiTE’s safety profile and minimizing cytokine release. Parallel development of a FAP‑specific PET tracer could enable clinicians to non‑invasively identify patients with high‑risk, FAP‑rich lesions and monitor therapeutic response in real time. If successful, this strategy may extend beyond coronary disease to other fibroinflammatory cardiovascular conditions, opening a new market segment for immuno‑based cardiovascular drugs and reshaping how clinicians manage residual atherosclerotic risk.